NR-026Ingredient Atlas entry · Compound

Phosphatidylserine

A phospholipid, one of the fats that make up cell membranes

A London doctor's thousand ox brains, a Catalan chemist kept from home by war, an Italian drug company and a cattle plague. Phosphatidylserine was found hiding in a brain fat in 1941. It was sold from cow brains for years, then made from soybeans, and one old number lived on.

  • Made from: soya, sunflower or fish
  • Most tested: 300 mg a day
  • Usually taken daily for weeks
Soybean pods on the plant at sunset
Soybean pods on the plant at sunset. Photo by United Soybean Board, CC BY 2.0, via Wikimedia Commons

The workman's brush

London, 1874. A workman turns a brush over a sieve of horsehair.1

The brush was a strong, round furniture brush, and he kept it turning without a pause. Under it, a pulp of minced brain was worked through a sieve so fine that every strand in its weave was made of eight single horse hairs.1

The brains were from oxen, more than a thousand of them, and they came from the butcher soaked in blood. The usual way to kill an ox was a blow of the pole-axe to the forehead, which punched a piece of skull into the brain. Then the slaughterman pushed a cane through the hole and down the spinal canal, and stirred it about to destroy the spinal cord.1

In the laboratory the brains were washed, skinned with fine forceps and dropped into strong alcohol to harden. If the alcohol was too weak, they stayed soft and rotted with "a fetid odour". The hardened brains went through a rotary mincing machine, and then to the brush.1

The man in charge was Johann Ludwig Wilhelm Thudichum, a German-born London doctor who did research for John Simon, the British government's medical officer.2 From 1870 to 1872 Thudichum had studied the chemistry of typhus, and his results could be no more than provisional. Nobody knew the chemistry of a healthy brain, so there was nothing to measure a sick one against.3 So he started again, with the healthy brain.2, 3

He could not get enough human brains that were perfectly fresh and free of disease. Oxen it had to be.1

He was taking the brain's fats apart, one by one. One of them he called kephalin. Inside it hid phosphatidylserine, and nobody would see it for another 67 years.1, 4

The chemical soul

In 1884 Thudichum put twelve years of work into one book, A Treatise on the Chemical Constitution of the Brain. He signed the preface that February from Pembroke Gardens, in Kensington in west London.5, 6

He had pulled a whole family of fats, the phosphatides, out of the brain. To him they were "the centre, life, and chemical soul of all bioplasm whatsoever, that of plants as well as animals".5

He hoped his chemistry would explain madness. Many forms of insanity, he wrote, came from "poisons fermented within the body". Once the brain's normal chemistry was known "to its uttermost detail", he had no doubt the poisons would be found, and then their antidotes.5

He made powerful enemies. The German pharmacologist Oscar Liebreich had drawn from the brain a substance called protagon, and held that it was one large molecule. Thudichum showed it was a mixture.2 In 1879 the journal he edited declared that the doctrine of protagon "has been properly rejected by all physiological chemists who know their business".6

The fight cost him. The criticism told against him, and after Simon retired he was pushed to end his government research. With no university post and no students to carry it on, his work was neglected and then forgotten.2

In 1901 the University of Giessen, where he had trained, honoured him fifty years on by renewing his diploma. It called him "a most celebrated exponent of the art of Medicine and Chemistry". A fortnight later he died of a stroke. At his own request, his papers were burned.2

Six years on, a King's College London chemist called Otto Rosenheim began to dig into the history of protagon. He was struck by Thudichum's work on it and set out to learn who this forgotten writer had been. In the end he won the dead man his credit.2

Three fats in one

Jordi Folch came to New York from Barcelona in 1936, a young doctor who wanted to learn the chemistry of medicine at the Rockefeller Institute.4

He meant to go home and fight in the Spanish Civil War for the Loyalists, the side that defended the Republic's government against an army rebellion. His family told him to stay.4

The whole family were Loyalists. Both his older brothers fought, and both had to flee to Toulouse. One day his father, a lawyer, businessman and prize-winning poet, heard that his name was on a list of people to be arrested the next day. He escaped to France by boat at once. Soon after, Folch's mother walked north through the Pyrenees, at night, in winter. Folch stayed on at the Rockefeller for nine years.4

His new ways of measuring fats needed pure brain fats as yardsticks, and he made them from the brains of cattle. Kephalin was supposed to be a single fat, as Thudichum had said. Folch measured what was in it, and the numbers did not fit.4

So he took it apart. In 1941 he and Howard Schneider reported an amino acid in ox-brain kephalin. It was serine, first found in silk and named after it.7, 8 By June he had pulled out the fat that carried it, phosphatidyl serine. In the papers that followed he showed that kephalin was not one fat but a mixture of at least three.4, 7

In 1944 McLean, a psychiatric hospital in Massachusetts, made him its director of research, and Harvard made him an assistant professor. His new laboratories there opened in 1946. The brains still came from cattle. At busy times his staff went to the local slaughterhouse almost every day. Then everyone, students, technicians and scientists alike, spent the day scraping grey matter off the brains with wooden tongue depressors. "For this I had to go to college?" one technician said.4

Cow brains at Abano Terme

In the 1980s the fat Folch had found was tested as a medicine, taken from cow brains, on people whose memory was failing.9

At Abano Terme, near Padua, the Italian drug company Fidia had its research laboratories, and its scientists published paper after paper on phosphatidylserine.10

In Bethesda, Maryland, Thomas Crook worked at a company called Memory Assessment Clinics. In 1991 he and his colleagues reported a trial of cow-brain phosphatidylserine in 149 people with what doctors call age-associated memory impairment. After twelve weeks the treated group did better than the placebo group on tests of learning and memory drawn from daily life. Those who had scored lowest at the start gained most.11

Two years later a scientist from Fidia's laboratories reported a trial in 494 older people with moderate to severe mental decline. They were treated for six months in 23 hospital units across north-east Italy. Those on the cow-brain fat did better than those on a placebo, in behaviour and in memory.12

Mad cows

By then a new disease had turned up in British cattle. Bovine spongiform encephalopathy was first described in the mid-1980s, and like the other diseases of its kind it left the brain looking like a sponge. It was carried by prions, unusual proteins that survive the usual ways of killing germs. In 1996 doctors in Britain described a new form of Creutzfeldt-Jakob disease, the human illness of the same kind, and the likely cause was beef from infected cattle.9

By then phosphatidylserine was also sold as a supplement, and until the mid-1990s it came only from cow brains. That suddenly looked risky.13

In 1996 Parris Kidd, a scientist who championed phosphatidylserine, wrote about it in the journal of the supplement company Thorne Research. With "the 'mad cow' disease epidemic in Great Britain", eating bovine brain "might be deemed a questionable practice". Soy phosphatidylserine was already on sale.13, 14

Soy phosphatidylserine is not pressed out of beans. It is made from soy lecithin, which holds the soybean's own membrane fats, by treating it with serine and an enzyme that turns those fats into phosphatidylserine.9

The new molecule was not quite the old one, so results from cow brains might not hold for soy. Its fatty acids were mostly polyunsaturated, while cow-brain phosphatidylserine carried mainly saturated ones and long-chain ones such as DHA.9

In Maastricht, a team gave soy phosphatidylserine or a placebo to 120 older people with memory complaints for twelve weeks. In 2001 they reported "no significant differences" between the groups "in any of the outcome variables".15

Little scientific evidence

In 2002 lawyers for a petitioner who made phosphatidylserine from soy wrote to the US Food and Drug Administration. They asked for supplement labels to be allowed to say that phosphatidylserine "may reduce the risk of dementia in the elderly".9

The agency read the trials. Most had used cow-brain phosphatidylserine and only two used soy, and all ten it weighed were "seriously flawed or limited in their reliability in one or more ways".9

On 13 May 2003 it said it would not act against labels that carried the claim. The agency's own words had to sit directly beneath it, in the same size of type.9

"Very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of dementia in the elderly. FDA concludes that there is little scientific evidence supporting this claim."9

A year and a half later the agency admitted two errors in how it had judged the trials. It looked at them again and kept every word of the warning.16

Twelve years younger

Crook's team had asked one more question of their 1991 trial. What did the gains mean for people's lives?13

They chose one test, learning to put names to faces, and a subgroup of 57 of the more impaired people, whose average age was 64. They calculated that on that test, cow-brain phosphatidylserine had brought them to the level of an average 52-year-old.13

In Kidd's 1996 retelling, phosphatidylserine had "rolled back the clock" by roughly 12 years. Two sentences later he added that this "can scarcely be called a reversal of age-associated memory impairment", though Crook's team thought the effect might matter to many patients and doctors. Eight pages on, in his conclusions, he put it more boldly. On names and faces, "PS reversed more than a decade of decline".13

By 2007 Kidd had written a short book on it. The book's blurb promises "a natural substance that can turn back the clock on aging". It says Crook's team "found that PS could restore up to 12 years worth of lost mental function".17

The twelve years outlived the cow brains. An article on the website of Natural Grocers, an American grocery chain, has a section headed "PS rejuvenates the aging brain, improves memory". Citing Crook's trial, it says "the researchers calculated that this subgroup's memory improved by 12 'functional' years". It does not say the trial used phosphatidylserine from cow brains. The chain's own guide says most of the supplements are now made from soy.18

Crook's figure was one calculation, on one test, for one subgroup taking a fat from cow brains. The soy trial in Maastricht found no real difference on any measure.13, 15

Soybean pods

Today phosphatidylserine is made from soya, sunflower or fish, and the trials of it, cow brain and soybean alike, are sorted on the Research tab.19

The fat Folch found has a job of its own. In a living cell it keeps to the inner face of the membrane. A team in Denver showed in 1992 that when a cell starts to die, the phosphatidylserine turns up on the outside. The body's clean-up cells, the macrophages, know it on sight and eat the dying cell.20

Thudichum had a thousand ox brains pushed through horsehair to find the fats of the mind. He had already said where else they lived. The chemical soul, he wrote in 1884, belonged to "plants as well as animals". You will find it in the soybean pods in the photograph at the top of this page.5

See what modern trials found

Myths and facts

In the record, or legend?

Every story you will read about this compound, checked against the oldest source we could find.

  • Thudichum worked through more than a thousand ox brains

    In the record

    His own 1874 report says so, with the sieve, the brush and the butcher's pole-axe1

  • Jordi Folch discovered phosphatidylserine in 1941

    In the record

    His 1941 papers on ox-brain kephalin, and his Academy memoir, which says "Folch discovered phosphatidyl serine"4, 7

  • The first phosphatidylserine supplements came from cow brains, until mad cow disease

    In the record

    Most of the early trials used cow-brain phosphatidylserine, and the switch to soy came with the BSE scare. The FDA still allowed cow-brain phosphatidylserine in 2003 from countries free of BSE9, 13, 14

  • The FDA allowed a dementia claim on phosphatidylserine labels

    In the record

    It said it would not act against a claim that phosphatidylserine "may reduce the risk of dementia in the elderly", so long as its own words sat beneath it, that "there is little scientific evidence supporting this claim"9, 16

  • Crook's trial showed phosphatidylserine can restore 12 years of lost memory

    Legend

    The figure was one calculation from a 1991 trial of cow-brain phosphatidylserine, for 57 of the more impaired people, on one test of names and faces. The FDA in 2003 judged such subgroup analyses "of questionable validity". Kidd's 1996 retelling first says it "can scarcely be called a reversal", then that "PS reversed more than a decade of decline", and the blurb of his 2007 book has it restoring "up to 12 years worth of lost mental function". The 2001 trial of soy phosphatidylserine found no significant differences, and the FDA said the two "may be different substances"9, 13, 15, 17, 18

  • Dying cells show phosphatidylserine so the body can clear them away

    In the record

    Shown in 1992 in Denver20

In the record means a source from the time, or a scholar quoting one, says it. Likely means a named expert's reasoned identification. Told, not shown means one interested party says it and nothing checks it. Partly means a real event sits under a bigger story. Legend means the earliest source is far too late or missing. Wrong date means the event is real but the popular date doesn't match the record.

Notes

Every fact in the story points to one of these. Where a translation is ours, the note says so.

Show all 20 notes Hide the notes
  1. J. L. W. Thudichum, "Researches on the Chemical Constitution of the Brain", Appendix No. 5 in Reports of the Medical Officer of the Privy Council and Local Government Board, New Series No. III (London: HMSO, 1874), pp. 113-114, https://archive.org/details/s4645id1397413 (Wellcome Collection copy; quotations and numbers checked against the page images). The contents on p. 113 list a "Sub-group of kephalines" among the "phosphorised principles". P. 113: "Anyone who would proceed to an extensive chemical investigation of the brain finds it impossible under ordinary circumstances to procure, in the perfectly fresh state, and with the perfect freedom from disease which are indispensable, such a supply of material from the human subject as will even approximately suffice for his purpose." P. 114: "Therefore, as material for the present very large inquiry, ox brains have in most part been preferred; and of these more than a thousand have been used. Five brains weigh on an average 1,780 grms., or eight weigh six pounds. They are washed once and freed from clotted blood. They are next carefully skinned, the arachnoid and pia mater being removed by means of fine anatomical forceps ... then submerged in methylated alcohol of 85 % ... For if the alcohol is too dilute ... the brains remain soft and unworkable, and decompose with a fetid odour ... When the brains are well hardened in the alcohol ... they are passed through a rotary mincing machine ... This pulp is now worked through a very fine hair sieve, having 144 meshes to the square inch, and each of the twelve strands of hair crossing the square inch in one direction, being composed of eight single horse hairs ... The trituration on the sieve is effected by a strong circular furniture brush, which is incessantly rotated over the sieve by the hands of a workman." Footnote on p. 114: "The ox brains as obtained from the butcher are generally much suffused with blood. This arises from the mode in which the animals are slaughtered; a blow is inflicted upon the frontal region with the pole-axe, whereby a piece of skull is punched in and pressed into the brain. Immediate unconsciousness and paralysis is the result. In addition to this the slaughterer destroys the spinal reflex-centres by introducing a cane through the hole in the skull into the spinal canal and destroying the marrow by stirring it about. The skull is afterwards cloven, and the brain taken out in two halves." The footnote describes "the mode in which the animals are slaughtered", which is why the story calls it the usual way. The blow brought "immediate unconsciousness", and the "marrow" in the spinal canal is the spinal cord. The dateline year is the year of the report; Simon (note 3) says the work had by then run "more than two years". "In most part" means some human brains were used as well. The 67 years run from this report to Folch's 1941 papers (note 7). ↩
  2. T. L. Sourkes, "Thudichum, Johann Ludwig Wilhelm", Complete Dictionary of Scientific Biography (Charles Scribner's Sons, 2008), via https://www.encyclopedia.com/science/dictionaries-thesauruses-pictures-and-press-releases/thudichum-johann-ludwig-wilhelm . Born Büdingen, Hesse-Darmstadt, 27 August 1829; died London, 7 September 1901. "Over a period of sixteen years, Thudichum labored at the chemical study of the human and animal brain, in the time he could spare from his medical practice." His work "brought him to the attention of John Simon, then medical officer of the Privy Council, who appointed him as a consultant"; "He recognized that he first needed information about the normal brain." "The most significant dispute concerned the nature of protagon, an extract that the German pharmacologist Oscar Liebreich had obtained from brain, and which he considered to be a unitary, high-molecular-weight substance. Thudichum showed that it was actually a mixture of lipids by characterizing its components. Although his stance was principled and generally correct in these various disputes, Thudichum's career was affected adversely by the criticisms, for after Simon's retirement he was pressured to terminate his government-sponsored work. He finally published his treatise on the chemistry of the brain, based upon his own studies, in 1884". Thudichum was involved in "scientific controversies that pitted him against powerful adversaries." "Lacking an academic post, Thudichum was not able to maintain a long-lasting cadre of research personnel that could develop into a 'school.' As a result, his work did not get the attention it deserved, and was neglected or forgotten. Otto Rosenheim, a lecturer on chemical physiology at King's College, London, began to investigate the history of protagon in 1907, and was especially impressed with the work of Thudichum on the subject. He became interested in discovering who that writer was, eventually achieving posthumous recognition for him." "In 1847 Ludwig was accepted for studies in medicine at the University of Giessen, but took part of his medical studies in Heidelberg." "Fifty years after his graduation Thudichum was honored by the University of Giessen with ceremonial renewal of his diploma. In it he was described as 'a most celebrated exponent of the art of Medicine and Chemistry.' A fortnight later he died of a cerebral hemorrhage. He was cremated, his papers were burned (by his request), and his library distributed." Sourkes also names his assistants, "the best known of these being James Alfred Wanklyn, Charles Thomas Kingzett, and Henry Wilson Hake"; the story's "no students to carry it on" stands for the lasting "school" he could not build. Sourkes says only that Liebreich "obtained" protagon, so the story does not say who named it. A cerebral haemorrhage is one kind of stroke. ↩
  3. J. Simon, introduction to Reports of the Medical Officer of the Privy Council and Local Government Board, New Series No. III (London: HMSO, 1874), pp. 8-9, https://archive.org/details/s4645id1397413 (checked against the page images). Pp. 8-9: Thudichum's paper "contains, so far as yet ripe for publication, the results of a very important and very laborious research, on which Dr. Thudichum has been engaged for more than two years ... During the years 1870-2, Dr. Thudichum ... had been investigating the chemistry of typhus; but after following as far as then seemed possible the chemical phenomena of that disease, had found that the results of his work could not properly be deemed more than provisional ... The difficulty ... consisted in the want of normal chemical standards by which to measure the morbid declensions in typhus ... clearly no true chemical knowledge of that morbid action would be possible, till greatly improved knowledge of the normal brain-chemistry should be supplied. Accordingly this task was taken in hand". ↩
  4. M. B. Lees and A. Pope, "Jordi Folch-Pi, March 25, 1911-October 3, 1979", Biographical Memoirs of the National Academy of Sciences 79 (2001), pp. 135-156, https://www.nationalacademies.org/read/10169/chapter/10 (PubMed 11762394). P. 135: Folch was "a colorful and truly unique personality", a "Catalan physician-scientist", "widely considered to have inherited the mantle of Johannes Thudichum"; his studies at the Rockefeller "showed that a brain lipid fraction called cephalin by Thudichum was actually a mixture of several components". P. 136: born in Barcelona on 25 March 1911; "His father, trained as a lawyer, was a successful businessman and a dedicated poet", who won "the Golden Violet prize" in the Floral Games, a Catalan literary contest. Pp. 137-138: the aim of his visit "was to learn biochemistry as applied to medicine under the direction of Dr. Donald D. Van Slyke"; "Folch intended to return to Spain, where he very much wanted to fight on the Loyalist side in the Spanish Civil War (1936-39), but his family urged him to remain in the United States. The entire Folch family were active Spanish Loyalists. His oldest brother, Alfred, a physician and surgeon, and his second brother, Frederic, an engineer, both fought for the Loyalists but had to flee to Toulouse at some point during the war ... One day, Folch's father received word that he was on a list of people to be arrested the next day, and he immediately escaped to France by boat and headed for Toulouse. Shortly thereafter, Folch's mother fled north and literally walked through the Pyrenees in a harrowing winter nighttime trip. Jordi acquiesced to his family's wishes, remaining at the Rockefeller Institute for a total of nine years." Wikipedia, "Republican faction (Spanish Civil War)", https://en.wikipedia.org/wiki/Republican_faction_(Spanish_Civil_War) , for the story's gloss: "also known as the Loyalist faction (Bando leal) ... was the side in the Spanish Civil War of 1936 to 1939 that supported the government of the Second Spanish Republic against the Nationalist faction of the military rebellion." P. 138: "Folch arrived at the Rockefeller in 1936 as a volunteer assistant." P. 139: "the first priority was to obtain purified lipids from bovine brains to be used as standards ... he characterized the isolated cephalin fraction. According to Thudichum ... this was pure phosphatidyl ethanolamine, but Folch showed that the amounts of carbon and of amines were not consistent with the accepted formula. This in turn led to a series of classic papers published in the Journal of Biological Chemistry showing that cephalin was not a single lipid but rather was a mixture of at least three lipids ... the isolation, purification, and characterization of phosphatidyl ethanolamine and a new amine-containing lipid entity identified as phosphatidyl serine." The "at least three" finding came from that series of papers, not from the June 1941 paper alone. Pp. 140-141: "McLean Hospital is a psychiatric affiliate of the Massachusetts General Hospital". P. 142: "In 1944 he was appointed director of scientific research at McLean and assistant professor of biological chemistry at Harvard Medical School"; "Folch enthusiastically threw himself into the task of planning a state-of-the-art building, while simultaneously continuing his research at Rockefeller. In May 1946 the new building was dedicated with a scientific symposium of distinguished speakers. By autumn the laboratories were fully operational with support staff that came with him from New York". P. 145: "there were periods when staff members went to the local slaughterhouse almost daily to obtain bovine brains. Everyone--students, technicians, postdoctoral fellows, and scientific staff--spent the day scraping gray matter from the brains using wooden tongue depressors. As one technician commented: 'For this I had to go to college?'" P. 148: "Folch discovered phosphatidyl serine". Kephalin and cephalin are two spellings of the same name. The memoir gives no year for his parents' escape, only that it was during the war. ↩
  5. J. L. W. Thudichum, A Treatise on the Chemical Constitution of the Brain, Based throughout upon Original Researches (London: Baillière, Tindall, and Cox, 1884), preface pp. vii-xiii, https://archive.org/details/b23984570 (Wellcome Collection copy; checked against the page images). P. vii (unnumbered, the first page of the preface): "It was under such unpromising conditions that I undertook, about twelve years ago, to make some researches on this subject for the then Medical Department of the Privy Council. The progress which I was able to report in 1874 was sufficiently great to ensure acquiescence in the continuance of my efforts". P. xii: "Phosphatides are the centre, life, and chemical soul of all bioplasm whatsoever, that of plants as well as animals." P. xiii: "Many forms of insanity are unquestionably the external manifestations of the effects upon the brain-substance of poisons fermented within the body ... These poisons we shall, I have no doubt, be able to isolate after we know the normal chemistry to its uttermost detail. And then will come in their turn the crowning discoveries to which all our efforts must ultimately be directed, namely, the discoveries of the antidotes to the poisons". The preface is signed "THE AUTHOR. 11, Pembroke Gardens, W., February, 1884." The W. is the West London postal district. Kensington is from his preface to the Annals of Chemical Medicine (note 6), signed from "11 Pembroke Gardens, Kensington, W" in September 1879. ↩
  6. J. L. W. Thudichum, "Note and experiments on the alleged existence in the brain of a body termed 'protagon'", Annals of Chemical Medicine 1 (London, 1879), pp. 254-263, https://archive.org/details/cu31924012287243 (Cornell University Library copy; checked against the page image). The volume's title page reads "Edited by J. L. W. Thudichum, M.D." P. 263: "It follows from the foregoing that the doctrine of 'protagon' has been properly rejected by all physiological chemists who know their business." The article is unsigned, headed "(From the Pathological Institute.)", so the story gives the line to the journal he edited rather than to him by name. ↩
  7. J. Folch and H. A. Schneider, "An amino acid constituent of ox brain cephalin", Journal of Biological Chemistry 137 (1941), pp. 51-62, https://doi.org/10.1016/S0021-9258(18)72976-1 ; J. Folch, "The isolation of phosphatidyl serine from brain cephalin, and identification of the serine component", Journal of Biological Chemistry 139 (June 1941), pp. 973-974, https://doi.org/10.1016/S0021-9258(18)72967-0 . Titles, volumes and dates from the Crossref records; the journal's site blocks automated readers, so the papers themselves were not read for this page, and what they found is taken from the memoir (note 4). Schneider's first name, Howard, is from the memoir's list of Folch's collaborators (p. 140). ↩
  8. Wikipedia, "Serine", https://en.wikipedia.org/wiki/Serine : "Serine was first obtained from silk protein, a particularly rich source, in 1865 by Emil Cramer. Its name is derived from the Latin for silk, sericum." ↩
  9. US Food and Drug Administration, letter from C. L. Taylor to J. W. Emord and A. G. Ferrenz, "Phosphatidylserine and Cognitive Dysfunction and Dementia (Qualified Health Claim: Final Decision Letter)", 13 May 2003, archived copy at https://webarchive.library.unt.edu/eot2008/20080917085614/http://www.cfsan.fda.gov/~dms/ds-ltr36.html (listed by the FDA at https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/qualified-health-claims-letters-enforcement-discretion). The petition, "submitted on April 19, 2002, on behalf of Doctor Kyl Smith", asked for "1) consumption of phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly, and 2) consumption of phosphatidylserine may reduce the risk of dementia in the elderly." Sources: "1) bovine brain cortex (BC-PS), and 2) soy lecithin (S-PS)"; "Your petition also states that the 'petitioner derives phosphatidylserine from soy lecithin'". Safety: lawful "provided that bovine-derived sources, if used, are not derived from bovine tissues from cattle born, raised, or slaughtered in any country where BSE exists"; its footnote 2 explains that the spongiform encephalopathies are "characterized by a sponge-like appearance of the brain and ... associated with deposits in the brain of unique proteins called prions. The prions can be transmitted from one host to another ... In the mid-1980s, a new TSE, bovine spongiform encephalopathy (BSE), was first described in cattle in the United Kingdom. Humans are also susceptible to TSEs, one form of which is Creutzfeldt-Jakob disease (CJD). In 1996, a new variant of CJD (vCJD) was described in patients in the United Kingdom. Epidemiological data implicate the consumption of beef products contaminated with the agent of BSE as the probable cause of vCJD in humans", and "materials and processes that destroy traditional human and animal pathogens do not appear to destroy prions". On the two sources: "the phosphatidylserine molecule from soy lecithin contains mainly polyunsaturated acids, while the phosphatidylserine molecule from bovine brain cortex contains mainly saturated and monounsaturated fatty acids and long-chain polyunsaturated fatty acids (e.g., docasahexaenoic acid)"; "S-PS is prepared from soy lecithin that has been treated with serine and an enzyme to convert the native phospholipids in soy lecithin to phosphatidylserine"; "FDA considers that bovine brain cortex- and soy lecithin-sources of phosphatidylserine may be different substances and may, therefore, have different biological activities." On the trials: "Most of the studies identified BC-PS as their test product" (twelve studies), and "Two studies used a soy-derived" phosphatidylserine (Jorissen et al., 2001; Schreiber et al., 2000); "Of the 10 intervention studies that formed the basis of FDA's evaluation, all were seriously flawed or limited in their reliability in one or more ways"; "most of the evidence does not support a relationship between phosphatidylserine and reduced risk of dementia or cognitive dysfunction, and ... the evidence that does support such a relationship is very limited and preliminary." On the subgroups: "Several studies conducted subgroup analyses that appeared to show stronger relationships between phosphatidylserine and outcome measures than were observed for the overall group results (Crook et al, 1992; Crook et al., 1991). However, these subgroup analyses are of questionable validity, given that randomization was not based on subgroup category". The wording allowed: "Consumption of phosphatidylserine may reduce the risk of dementia in the elderly. Very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of dementia in the elderly. FDA concludes that there is little scientific evidence supporting this claim." (with a matching claim and disclaimer for cognitive dysfunction). FDA "intends to consider exercising enforcement discretion" when "the applicable disclaimer is placed immediately adjacent to and directly beneath your claims, with no intervening material, in the same size, typeface, and contrast as the claim itself". The disclaimers were the FDA's own offer: "your client agreed to the terms proposed by FDA, as modified during the negotiations". "Enforcement discretion" means the agency would not act against labels that kept to these terms; it is not an approval. The story's "lawyers" are Emord and Associates, to whom the letter is addressed. ↩
  10. Wikipedia (Italian), "Fidia Farmaceutici", https://it.wikipedia.org/wiki/Fidia_Farmaceutici : "una società italiana operante nel settore farmaceutico" (an Italian company in the pharmaceutical sector), founded in Bologna in 1946, with its headquarters moved to Abano Terme, in the province of Padua, in 1959. PubMed lists 22 papers on phosphatidylserine with a Fidia affiliation (search "(phosphatidylserine) AND (Fidia[Affiliation])", 16 November 2026), two of them from the "Fidia Georgetown Institute for the Neurosciences" in Washington, DC; for example C. Monastra and others, 1991, from "Fidia Research Laboratories, Abano Terme, Italy". Our translation. ↩
  11. T. H. Crook and others, "Effects of phosphatidylserine in age-associated memory impairment", Neurology 41 (1991), pp. 644-649, abstract at https://pubmed.ncbi.nlm.nih.gov/2027477/ (https://doi.org/10.1212/wnl.41.5.644 ; the publisher blocks automated readers, so only the abstract was read). Affiliation "Memory Assessment Clinics, Inc., Bethesda, MD". "We treated 149 patients meeting criteria for age-associated memory impairment (AAMI) for 12 weeks with a formulation of phosphatidylserine (... BC-PS ...) or placebo. Patients treated with the drug improved relative to those treated with placebo on performance tests related to learning and memory tasks of daily life. Analysis of clinical subgroups suggested that persons within the sample who performed at a relatively low level prior to treatment were most likely to respond to BC-PS." BC-PS is phosphatidylserine from bovine brain cortex (note 9). PubMed gives Crook's initials, T. H.; the first name is from Kidd (note 13, p. 71), "Thomas Crook, PhD, and his collaborators at the Memory Assessment Clinics (MAC)". That the lowest scorers gained most came from an analysis of subgroups, which the FDA called "of questionable validity" (note 9). Only Crook's affiliation is listed. A co-author, M. G. Nunzi, has the same name and initials as a scientist at Fidia Research Laboratories, Abano Terme, who published on cow-brain phosphatidylserine in old rats (PubMed 3431625, 1987, and 2602444, 1989); the abstract does not say who made the phosphatidylserine or paid for the trial. ↩
  12. T. Cenacchi and others, "Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration", Aging (Milano) 5 (1993), pp. 123-133, abstract at https://pubmed.ncbi.nlm.nih.gov/8323999/ (https://doi.org/10.1007/BF03324139 ; the publisher blocks automated readers, so only the abstract was read). First author's affiliation "Fidia Research Laboratories, Abano Terme (Padova), Italy". "This double-blind study assesses the therapeutic efficacy and the safety of oral treatment with phosphatidylserine (BC-PS) vs placebo ... for 6 months ... A total of 494 elderly patients (age between 65 and 93 years), with moderate to severe cognitive decline ... were recruited in 23 Geriatric or General Medicine Units in Northeastern Italy. Sixty-nine patients dropped out within the 6-month trial period ... Statistically significant improvements in the phosphatidylserine-treated group compared to placebo were observed both in terms of behavioral and cognitive parameters." The memory test used was the Buschke Selective Reminding Test. Kidd (note 13, p. 74) gives "425 subjects", which is the 494 recruited less the 69 who dropped out. ↩
  13. P. M. Kidd, "Phosphatidylserine; Membrane Nutrient for Memory. A Clinical and Mechanistic Assessment", Alternative Medicine Review 1, no. 2 (1996), pp. 70-84, "Copyright©1996 Thorne Research, Inc.", read from a copy hosted by a supplement seller, https://cdn.shopify.com/s/files/1/0259/0110/5186/files/PS_research.pdf . The byline is "Parris M. Kidd, PhD". Thorne, "Thorne celebrates 40 years of good health", https://thorne.com/take-5-daily/article/thorne-celebrates-40-years-of-good-health (read 16 November 2026), calls Thorne "a supplement company" and the journal "Alternative Medicine Review®, Thorne's very own peer-reviewed, MEDLINE-indexed journal". Abstract (p. 70): "Until recently, supplemental PS was available only from bovine brain. Now PS is available as a soy lecithin-based concentrate. With its proven benefits against age-related mental decline, phosphatidylserine might represent a truly safe and effective means for improving the quality of life of the elderly." The story's "until the mid-1990s" reads "until recently" from the article's date. P. 73, on the 1991 trial (his ref. 3, Crook and others): "A subgroup of 57 subjects who were relatively more memory-impaired, and slightly older (64.3 average age) seemed to benefit more from PS ... Encouraged by these findings, the investigators returned to their data to attempt to answer a crucial question: What meaning, if any, do these findings have for the subjects' quality of life? They took as their model the parameter name-face acquisition. They calculated that for the older, more affected subgroup, PS had 'rolled back the clock' by roughly 12 years. In other words, from being at an average 'cognitive age' equivalent to the average 64-year-old, these subjects were restored on average to a cognitive age of 52. This can scarcely be called a reversal of age-associated memory impairment by PS, but in the authors' words, 'The magnitude of effect may be considered significant by many subjects and clinicians.'" (checked against the page image). P. 80: "Prior to the advent of soy PS, clinical studies were done with a PS-enriched phospholipid fraction extracted from bovine brain ... the only source of PS linked with DHA is bovine brain, and with the 'mad cow' disease epidemic in Great Britain, the dietary consumption of bovine brain might be deemed a questionable practice." P. 81, in the conclusions (checked against the PDF text): "Dietary supplementation with PS can help slow the loss of some brain functions, and partially rejuvenate others—in one U.S. double-blind trial, on name-face recall PS reversed more than a decade of decline." with his ref. 3, Crook and others, 1991. The story's "eight pages on" counts from p. 73 to p. 81. The 12-year figure is told here as Kidd reports it. He gives no date or place for the investigators' return to their data, and cites it to the 1991 paper itself. Crook's full paper (note 11) was not read, so whether the phrase "rolled back the clock" is the authors' or Kidd's is not known. Kidd's "Two sentences later" counts from "rolled back the clock". ↩
  14. M. Kingsley, "Effects of phosphatidylserine supplementation on exercising humans", Sports Medicine 36 (2006), pp. 657-669, abstract at https://pubmed.ncbi.nlm.nih.gov/16869708/ (https://doi.org/10.2165/00007256-200636080-00003): "due to the possibility of transferring infection through the consumption of prion contaminated brain, S-PtdSer is the preferred supplement". M. Schreiber and others, "An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline", Israel Journal of Psychiatry and Related Sciences 37 (2000), pp. 302-307, abstract at https://pubmed.ncbi.nlm.nih.gov/11201936/ , names the "possible hazards involved in the treatment with bovine derivative of PS". Wikipedia, "Phosphatidylserine", https://en.wikipedia.org/wiki/Phosphatidylserine : "Initially, phosphatidylserine supplements were derived from bovine cortex. However, due to the risk of potential transfer of infectious diseases such as bovine spongiform encephalopathy (or 'mad cow disease'), soy-derived supplements became an alternative." Cow-brain phosphatidylserine had not vanished: in 2003 the FDA still allowed it from countries free of BSE (note 9). ↩
  15. B. L. Jorissen and others, "The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment", Nutritional Neuroscience 4 (2001), pp. 121-134, abstract at https://pubmed.ncbi.nlm.nih.gov/11842880/ (https://doi.org/10.1080/1028415x.2001.11747356 ; the publisher blocks automated readers, so only the abstract was read). Affiliation: Brain & Behaviour Institute, Maastricht. "Subjects were 120 elderly (> 57 years) of both sexes who fulfilled the more stringent criteria for age-associated memory impairment ... allocated at random to one of the three treatment groups: placebo" or one of two amounts of soy PS; assessed "after 6 and 12 weeks of treatment". "No significant differences were found in any of the outcome variables between the treatment groups ... In conclusion, a daily supplement of S-PS does not affect memory or other cognitive functions in older individuals with memory complaints." Later trials of soy phosphatidylserine report mixed results: for example a 2010 Japanese trial in 78 people (A. Kato-Kataoka and others, Journal of Clinical Biochemistry and Nutrition 47, pp. 246-255, https://doi.org/10.3164/jcbn.10-62). The Research tab sorts them. ↩
  16. US Food and Drug Administration, letter from W. K. Hubbard to J. W. Emord, "Letter Updating the Phosphatidylserine and Cognitive Function and Dementia Qualified Health Claim", 24 November 2004, archived copy at https://webarchive.library.unt.edu/eot2008/20080917093956/http://www.cfsan.fda.gov/~dms/ds-ltr39.html : "FDA was in error in its May 2003 letter of enforcement discretion stating that all the studies were in a diseased population"; "FDA was also in error in concluding that mitigation studies in diseased populations alone constituted credible evidence to substantiate the proposed claims"; "FDA continues to believe that the science provides very limited and preliminary evidence sufficient for qualified health claims about phosphatidylserine and reduced risk of these conditions, with the same qualifying language and enforcement discretion factors as outlined in the May 2003 letter." ↩
  17. Menrva Books, "PS (PhosphatidylSerine) Nature's Brain Booster: A Vital Lipid Nutrient for Memory, Mood and Stress" by Parris M. Kidd (Totalhealth, 1 November 2007, 96 pages, ISBN 9780977423217), https://www.menrvabooks.com/book/17447905 (a bookseller's page that earns from Amazon sales; read 16 November 2026). Product description: "This book is an easy read on a natural substance that can turn back the clock on aging ... In a double-blind trial with healthy over-50s subjects, famed memory researcher Dr. Tom Crook and his team found that PS could restore up to 12 years worth of lost mental function ... Used for decades in Europe as a dietary supplement, PS was introduced into North America by a visionary team with Dr. Kidd as their technical resource." Who wrote the description is not stated, and the book itself was not read for this page. Crook's 1991 trial was in people with age-associated memory impairment (note 11). Found by a web search for "phosphatidylserine 'rolled back the clock' 12 years Crook memory", 16 November 2026. ↩
  18. L. Wilson, "Phosphatidylserine (PS), a Love Letter to Your Brain (PS, your brain will thank you)", Natural Grocers, https://www.naturalgrocers.com/health-hotline-article/phosphatidylserine-ps-love-letter-your-brain-ps-your-brain-will-thank-you (read 16 November 2026; the Internet Archive lists a copy from 16 October 2021, http://web.archive.org/web/20211016160954/https://www.naturalgrocers.com/health-hotline-article/phosphatidylserine-ps-love-letter-your-brain-ps-your-brain-will-thank-you , which could not be opened for this page). Natural Grocers is a grocery chain that sells supplements. Section heading "PS rejuvenates the aging brain, improves memory"; "One trial treated 149 patients over the age of 50 with age-associated memory impairment ... for 12 weeks. At the end of the trial, the supplemented group had improvements in learning and memory/recall, and those who performed at the lowest level when the study began saw the most improvement. The researchers calculated that this subgroup's memory improved by 12 'functional' years." Its note 4 is Crook and others, 1991 (note 11). The article does not mention the source of the phosphatidylserine used in that trial. Natural Grocers, "Phosphatidylserine (PS) – Frequently Asked Questions", https://www.naturalgrocers.com/article/phosphatidylserine-ps-frequently-asked-questions (read 16 November 2026): "PS supplements are most commonly derived from soy lecithin, but there are also versions derived from sunflower lecithin". The short address https://www.naturalgrocers.com/phosphatidylserine leads to the same article. ↩
  19. Nooroots Ingredient Atlas, "Phosphatidylserine" (Research tab), https://www.nooroots.com/pages/phosphatidylserine-research : made from "soya, sunflower or fish"; "every study in people we could find, sorted". ↩
  20. V. A. Fadok and others, "Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages", Journal of Immunology 148 (1992), pp. 2207-2216, abstract at https://pubmed.ncbi.nlm.nih.gov/1545126/ . Affiliation: National Jewish Center for Immunology and Respiratory Medicine, Denver. "macrophages specifically recognize phosphatidylserine that is exposed on the surface of lymphocytes during the development of apoptosis"; "apoptotic lymphocytes lose membrane phospholipid asymmetry and expose phosphatidylserine on the outer leaflet of the plasma membrane. Macrophages then phagocytose apoptotic lymphocytes after specific recognition of the exposed PS." The work used mouse and rat cells. Wikipedia, "Phosphatidylserine" (note 14): "It is almost entirely found in the inner monolayer of the membrane with only less than 10% of it in the outer monolayer." ↩